Skip to main content

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012
July 17, 2020
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib
July 06, 2020
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine
June 12, 2020
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 05, 2020
ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress
May 21, 2020
ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress
Download PDF format download (opens in new window)
May 19, 2020
ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield
May 14, 2020
ADC Therapeutics Announces Pricing of Upsized Initial Public Offering
Download PDF format download (opens in new window)
May 11, 2020
ADC Therapeutics Announces Launch of Initial Public Offering
Download PDF format download (opens in new window)
May 01, 2020
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
Download PDF format download (opens in new window)
April 27, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors
Download PDF format download (opens in new window)
April 24, 2020
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
Download PDF format download (opens in new window)
April 21, 2020
ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer
Download PDF format download (opens in new window)
March 19, 2020
ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
Download PDF format download (opens in new window)
January 10, 2020
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
Download PDF format download (opens in new window)
January 09, 2020
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Download PDF format download (opens in new window)